Key Takeaways
- • InterCure secured NIS 22 million (approximately $7.4 million) in private placement financing led by leading pharma-focused hedge funds, with potential expansion to NIS 54 million ($18.6 million) through warrant exercises.
- • The company will issue 7,895,143 ordinary shares at NIS 2.75 (approximately $0.94) per share, representing a premium to the current trading price and reflecting investor confidence in the platform.
- • Funding commits to support global expansion initiatives, particularly in Germany and regulated U.S. medical cannabis markets, advancing InterCure's geographic diversification strategy.
- • Lead investors include key shareholders of the company alongside CEO Alexander Rabinovich, signaling internal stakeholder alignment with the capital raise and growth trajectory.
- • The financing represents a critical liquidity event for InterCure (INCR.TA), which has underperformed broader markets significantly, with stock down 53.08% over the three-year period ending June 22, 2026.
Summary
InterCure Ltd. announced the closing of a private placement financing totaling NIS 22 million (approximately $7.4 million), led by established pharma-focused hedge funds. The transaction includes binding commitments that could expand to NIS 54 million (approximately $18.6 million) upon the exercise of attached warrants, providing the cannabis and pharmaceutical company with meaningful capital flexibility. The financing reflects investor appetite for InterCure's expansion strategy and demonstrates validation from institutional players focused on the pharmaceutical and cannabis sectors.
Under the terms of the private placement, InterCure will issue 7,895,143 ordinary shares at NIS 2.75 per share, translating to approximately $0.94 per share. This pricing represents a premium to prevailing market levels and suggests strong investor conviction regarding the company's valuation and near-term prospects. The share issuance structure provides downside protection for new investors while maintaining upside participation through warrant provisions.
The capital raise is earmarked for global expansion efforts, with particular emphasis on two strategic markets: Germany and regulated U.S. medical cannabis jurisdictions. These geographic initiatives align with InterCure's broader strategy to diversify revenue streams beyond its existing operational footprint. The involvement of CEO Alexander Rabinovich and other key company shareholders alongside external hedge fund investors demonstrates alignment between management, existing stakeholders, and new capital providers on the company's strategic direction.
InterCure's equity performance has been challenged in recent years. The stock declined 53.08% over the three-year period ending June 22, 2026, significantly underperforming the S&P 500's 71.45% gain during the same window. Year-to-date performance as of the announcement date reflected a decline of 1.45%, further underscoring the market's cautious positioning. The private placement financing, combined with the company's strategic initiatives in high-growth cannabis and pharmaceutical markets, represents management's effort to restore investor confidence and drive operational momentum.
Under the terms of the private placement, InterCure will issue 7,895,143 ordinary shares at NIS 2.75 per share, translating to approximately $0.94 per share. This pricing represents a premium to prevailing market levels and suggests strong investor conviction regarding the company's valuation and near-term prospects. The share issuance structure provides downside protection for new investors while maintaining upside participation through warrant provisions.
The capital raise is earmarked for global expansion efforts, with particular emphasis on two strategic markets: Germany and regulated U.S. medical cannabis jurisdictions. These geographic initiatives align with InterCure's broader strategy to diversify revenue streams beyond its existing operational footprint. The involvement of CEO Alexander Rabinovich and other key company shareholders alongside external hedge fund investors demonstrates alignment between management, existing stakeholders, and new capital providers on the company's strategic direction.
InterCure's equity performance has been challenged in recent years. The stock declined 53.08% over the three-year period ending June 22, 2026, significantly underperforming the S&P 500's 71.45% gain during the same window. Year-to-date performance as of the announcement date reflected a decline of 1.45%, further underscoring the market's cautious positioning. The private placement financing, combined with the company's strategic initiatives in high-growth cannabis and pharmaceutical markets, represents management's effort to restore investor confidence and drive operational momentum.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.